UvA-DARE (Digital Academic Repository) Inhibitor development in nonsevere hemophilia A Eckhardt, C.L. Link to publication

Transcription

1 UvA-DARE (Digital Academic Repository) Inhibitor development in nonsevere hemophilia A Eckhardt, C.L. Link to publication Citation for published version (APA): Eckhardt, C. L. (2014). Inhibitor development in nonsevere hemophilia A General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam ( Download date: 26 Jan 2019

2 Portfolio Name PhD student: C.L. de Groot Eckhardt PhD period: January 2008 September 2014 Year ECTS 1.PhD training General Courses Advanced Topics in Clinical Epidemiology Scientific writing in English for Publication Cochrane systematic reviews Communication (UvA) Good Clinical Practice (BROK) Practical Biostatistics Clinical data management Clinical epidemiology Evidence Based Searching Project Management (UvA) Specific courses Training Upcoming Leaders in Paediatric Science (TULIPS) PhD curriculum Clinical epidemiology course Schiermonnikoog, dept of clinical epidemiology, LUMC, Leiden VNVA Kadertraining, Ina Vader, Amersfoort Dag voor de jonge onderzoekers, NVK, Veldhoven PhD course hemophilia (2008) and arterial thrombosis (2009) (NVTH) Advanced course on lab and clinical aspects of hemophilia (NVHP/EKZ/UMCG), Eerbeek, The Netherlands Seminars, Workshops and Master classes Grant writing course, ZonMW, the Hague Herfstpalet, Pediatric Hematology, EKZ, Amsterdam Immunology afternoon by Polly Matzinger, Sanquin, Amsterdam Masterclass of the EKZ Symposium,Amsterdam Workshop on ITI, Brussels, Belgium NWO talent class creative thinking, NWO, The Hague Weekly department journal club, dept of Vascular Medicine, AMC Weekly department clinical education, dept of Vascular Medicine, AMC Weekly department clinical education, dept of Pediatric Hematology, EKZ Oral presentations (first author only) Factor VIII gene (F8) Mutation and Inhibitor Development in Non- Severe Hemophilia A. XXIV ISTH Congress, Amsterdam, The Netherlands Inhibitor formation in nonsevere hemophilia A. 5th Inhibitor symposium, Nijmegen, The Netherlands INSIGHT in inhibitors in non-severe hemophilia A. 6 th annual EAHAD Congress, Warsaw, Poland Polymorphism 131R>H in the FCGR2A gene is associated with inhibitor development in Hemophilia A. 244

3 XXX WFH Congress, Paris, France Inhibitor development in mild and moderate hemophilia A. 7th Global Forum, World Federation of Haemophilia. Montreal, Canada Sevenfold risk for inhibitors in mild/moderate hemophilia A with factor VIII missense mutations in two distinct regions. XXIII ISTH Congress. Kyoto, Japan NVTH Congress, Koudekerke, The Netherlands Not mild at all: Viral infections (HIV, HBV, HCV) are present in over one third of 2600 mild and moderate hemophilia A patients and cause 24% of the observed 30 year mortality. XXIII ISTH Congress. Kyoto, Japan Inhibitor development in mild and moderate hemophilia A seems to be associated with an increased mortality risk. XXIII ISTH Congress. Kyoto, Japan for inhibitor development in mild and moderate hemophilia A: first results from the INSIGHT study. XXIX WFH congress. Buenos Aires, Argentine Intensive perioperative use of factor VIII and the Arg593 Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. 31st NVK symposium, Veldhoven, The Netherlands NVTH symposium, Koudekerke, The Netherlands Insight study: International study on etiology of inhibitors in patients with a moderate or mild form of hemophilia A, influences of immuno genetic & hemophilia treatment factors. 4th Inhibitor Symposium. Nijmegen, The Netherlands Poster presentations (first author only) Clinical presentation of inhibitor development in nonsevere haemophilia A. XXXI WFH Congress, Melbourne, Australia Identification of 18 High Risk F8 Mutations for Inhibitor Development in 2,700 Non-Severe Hemophilia A Patients. XXX WFH Congress, Paris, France Wide variation in factor VIII plasma levels in mild and moderate hemophilia A patients with the same missense mutation is presently unexplained. XXIII ISTH Congress, Kyoto, Japan for inhibitor development in mild and moderate hemophilia A: first results from the INSIGHT study. NVTH symposium, Koudekerke New INSIGHT in inhibitor development in mild/moderate hemophilia A : inhibitors arise after more exposure days than in severe disease. XXIX WFH congress, Buenos Aires, Argentine Treatment & its complications in mild and moderate hemophilia A: three decades of experience; first results of a European cohort study (INSIGHT). XXIX WFH congress. Buenos Aires, Argentine Surgery and inhibitor development in hemophilia A: a systematic review. XXIX WFH congress. Buenos Aires. Argentine NVTH symposium. Koudekerke; for inhibitor development in mild and moderate hemophilia A: 245

4 first results from the INSIGHT study. NVTH symposium, Koudekerke New INSIGHT in inhibitor development in mild/moderate hemophilia A: inhibitors arise after more exposure days than in severe disease. XXIX WFH congress, Buenos Aires, Argentine Intensive peri-operative use of factor VIII and the Arg593 Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. XXII ISTH Congress. Boston, USA Hematology Conference. Riga, Latvia Conferences 6th annual congress of the European Association for Haemophilia and Allied Disorders (EAHAD), Warsaw, Poland XXX World Federation of Haemophilia (WFH) Congress, Paris, France Amsterdam Kinderziekenhuis Symposium (AKS), Amsterdam, The Netherlands. 2011,12, Rodin symposium, Amsterdam, The Netherlands th Global Forum, WFH, Montreal, Canada e Pediatrische Transfusie symposium, Sanquin, Amsterdam, The Netherlands Van Creveld Symposium, Utrecht, The Netherlands XXIII International Society of Thrombosis and Haemostasis (ISTH) Congress, Kyoto, Japan Global Nurse Symposium, Zurich, Switserland XXIX WFH Congress, Buenos Aires, Argentine Hematology conference, Athens, Greece Hematology conference, Riga, Latvia XXII ISTH Congress, Boston, USA Dutch Society on Pediatrics (NVK) symposium, Veldhoven, The Netherlands. 2009,11, Inhibitor symposium, Nijmegen, The Netherlands. 2009, Emma Children s Hospital (EKZ) symposium, Amsterdam, The Netherlands Dutch Society on Thrombosis and Haemostasis (NVTH) Symposium, Koudekerke, The Netherlands st annual congress of the EAHAD, Amsterdam, The Netherlands XXVIII WFH Congress, Istanbul, Turkey Teaching Lecturing Risk factors for inhibitor development. Haemophilia and Rare Bleeding Disorders Training Camp. Kopenhagen, Denmark Intensive treatment and inhibitors in mild/moderate hemophilia A: the INSIGHT study. Rodin symposium. Amsterdam, The Netherlands Inhibitors: predict, prevent & treat. Global Nurse Symposium. Zurich, Switserland Inhibitor development in mild and moderate hemophilia A. Baxter and Sanquin symposium, ISTH conference. Boston, USA

5 Supervising Annieke van Baar, master thesis Esmée Krouwel, scientific internship Bo van Tienoven, master thesis Charlotte Kruijt, master thesis Albert Jansen, scientific internship Alessia van Eijkelenburg, master thesis Olivier Rijssenbeek, scientific internship Joy van der Pol, scientific internship Nina Streefkerk, master thesis Mira van der Naald, master thesis Other Consultant coagulation, lipid disorders and hypertension, dept of Vascular Medicine, Academic Medical Center Amsterdam, the Netherlands Organisation of INSIGHT study investigator meetings in Istanbul ( 08), San Francisco ( 08), Boston ( 09) and Buenos Aires ( 10) Parameters of esteem Grants, awards and prizes Young researchers award, XXX WFH Congress, Paris, France Science Prize, The Netherlands Society on Thrombosis and Hemostasis, Koudekerke, the Netherlands Young Investigators Award. XXIII ISTH Congress, Kyoto, Japan ZonMw Agiko Stipendium (nr ), The Hague, the Netherlands